Generated by AI
Firefly Neuroscience Inc. is a medical technology and artificial intelligence company focused on neuroscientific solutions for mental illnesses and neurological disorders. Its core product is the FDA-cleared Brain Network Analytics platform, which analyzes EEG and ERP data to help clinicians evaluate brain function and support diagnostic and treatment decisions. The company’s offerings are designed for use in settings addressing conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and other cognitive or neurological disorders. Firefly Neuroscience also provides the Evoke System, a brain assessment tool that generates structured reports from neurophysiological data. The company serves clinicians and other healthcare professionals across North America, positioning itself within the growing field of digital brain health and precision neuroscience.
Website1100 Military Road
Kenmore, NY, 14217
United States
The latest articles about AIFF.
Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.
Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS) shares moved
Summary of Sep 28's posts. Generated by AI.
Summary of Sep 25's posts. Generated by AI.
Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more
Summary of Sep 28's posts. Generated by AI.
Investors talking about AIFF also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.